Zinc-Charged Insulin Oral Delivery via Ion Cloud Protection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for administering insulin, such as subcutaneous injections, are invasive, prone to complications, and do not mimic the natural physiological and pharmacokinetic conditions of insulin production, while oral administration is challenging due to insulin degradation in the stomach, lacking an effective, FDA-approved oral insulin product.
Innovation Solution
A zinc-charged insulin composition is developed, where loosely bound surface ions on insulin molecules are removed using a chelating agent and replaced with zinc, creating a 'zinc ion cloud' that protects insulin from stomach acid and enzymes, allowing it to be absorbed through the gastrointestinal tract.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If insulin is administered through subcutaneous injection, then effective absorption by the body is achieved, but injection site complications and pain occur
Solution Approach 1:
The patent uses an absorption enhancer as an intermediary substance that facilitates insulin absorption through the intestinal wall without requiring injection. The absorption enhancer temporarily modifies the intestinal membrane permeability, allowing insulin to pass through while minimizing damage and inflammation, thus resolving the contradiction between effective delivery and avoiding injection site complications
Solution Approach 2:
The patent replaces the mechanical injection system with a chemical absorption enhancement system. Instead of using physical force (needle injection) to deliver insulin into the tissue, the invention uses chemical agents (absorption enhancers) to facilitate passive diffusion of insulin through the intestinal wall into the bloodstream, eliminating the need for mechanical penetration and associated complications
2Reliability
If insulin is administered through subcutaneous injection, then effective absorption is achieved, but the pharmacokinetic conditions do not reflect natural insulin production
Solution Approach 1:
The patent inverts the traditional administration route by delivering insulin through the oral gastrointestinal tract rather than through subcutaneous injection. This inversion allows insulin to follow the natural physiological pathway it would take if secreted by the pancreas, where it would naturally be absorbed into the portal circulation and delivered to the liver first, thereby restoring pharmacokinetic similarity to natural insulin production
3Stability of the object's composition
If insulin is administered orally, then natural physiological and pharmacokinetic conditions are reflected, but insulin is destroyed by stomach acid and enzymes
Solution Approach 1:
The patent applies preliminary protective action by pre-coating insulin molecules with absorption enhancers and protective polymers before oral administration. This preliminary encapsulation protects the insulin from stomach acid and enzymes during gastric passage, preventing degradation before the insulin can reach the absorption site in the intestinal wall
Solution Approach 2:
The patent converts the harmful acidic environment of the stomach into a beneficial controlled-release mechanism. The absorption enhancers and protective coatings are designed to be stable in acidic conditions, allowing the insulin to survive gastric passage intact, then release the insulin in the intestinal environment where absorption can occur, thus converting the previously harmful stomach environment into a manageable delivery phase
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The zinc-charged insulin effectively survives stomach conditions, is absorbed into the bloodstream, and provides long-lasting glucose regulation, reducing the frequency of administration and minimizing injection site complications, as demonstrated by significant reductions in blood glucose levels in both mice and human subjects.
Implementation Method 1
replacing all the loosely bound surface ions with Zinc... creating a 'zinc ion cloud' that protects insulin from stomach acid and enzymes
Implementation Method 2
removing any loosely bound surface ions present on a general insulin molecule using a chelating agent
Implementation Method 3
allowing it to be absorbed through the gastrointestinal tract
Data Source
AI summary
This invention is directed to a zinc-charged insulin composition that is effective in treating diabetes and lowering and stabilizing blood glucose levels when administered orally. The zinc-charged insulin is acid and enzyme resistant, such that the zinc-charged insulin is capable of surviving the acidic conditions of the stomach. The zinc-charged insulin is capable of being absorbed through the gastrointestinal tract and stored in the liver, such that the zinc-charged insulin is long lasting and pharmacokinetically similar to the insulin normally generated by the body. The invention is further directed to a method of preparing the zinc-charged insulin composition, including: (1) removing any loosely bound surface ions present on an insulin molecule using a chelating agent; and (2) replacing all the loosely bound surface ions with zinc.